A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter Study of Tucidinostat in Combination With CHOP in Newly Diagnosed Peripheral T-Cell Lymphoma With Follicular Helper of T Cell Phenotype (SWIFT 02)

A Randomised, Double-blind, Multicenter Phase Ⅲ Study to Evaluate the Efficacy and Safety of Tucidinostat versus Placebo in Combination with CHOP in Newly Diagnosed Peripheral T-Cell Lymphoma with Follicular Helper of T Cell Phenotype

开始日期2025-06-01

申办/合作机构

深圳微芯生物科技股份有限公司

NCT06570447

/ Recruiting临床2期IIT

An Open-label, Single-arm, Single-center, Phase II Clinical Trial of Glofitamab Combination With Chidamide in Patients With Recurrent and Refractory Diffuse Large B-Cell Lymphoma

An open-label, single-arm, single-center, phase II clinical trial to evaluate the feasibility, efficacy and safety of Glofitamab Combination with chidamide in patients with recurrent/refractory diffuse large B-cell lymphoma.

开始日期2025-05-15

申办/合作机构

天津市肿瘤医院（天津医科大学肿瘤医院）

NCT06951997

/ Not yet recruiting临床2期IIT

Clinical Study on the Efficacy and Safety of Iparomlimab and Tuvonralimab Injection Combined With Chidamide, Albumin-bound Paclitaxel and Gemcitabine as First-line Treatment for Metastatic Pancreatic Cancer

This is a single-center, open-label, exploratory study aims to assess the efficacy and safety of QL1706 plus nab-paclitaxel and gemcitabine as first-line treatment for patients with metastatic pancreatic adenocarcinoma.

开始日期2025-05-15

申办/合作机构

天津市肿瘤医院（天津医科大学肿瘤医院）

100 项与西达本胺相关的临床结果

登录后查看更多信息

100 项与西达本胺相关的转化医学

登录后查看更多信息

100 项与西达本胺相关的专利（医药）

登录后查看更多信息

2,860

项与西达本胺相关的文献（医药）

2025-06-01·JOURNAL OF PAIN

A Triple combination formulation of an HDAC inhibitor treats chronic pain in rodent spared nerve injury model

Article

作者: Alam, Md Suhail ; Haldar, Kasturi ; Vania Apkarian, A ; Centeno, Maria V

Histone deacetylase inhibitors (HDACi) that modulate epigenetic regulation and are approved for treating rare cancers have, in disease models, also been shown to mitigate neurological conditions, including chronic pain. They are of interest as non-opioid treatments, but achieving long-term efficacy with limited dosing has remained elusive. Here we employ a triple combination formulation (TCF) that includes the pan-HDAC vorinostat (Vo) administered at its FDA-approved daily dosage of 50 mg/Kg, along with the caging agent 2-hydroxypropyl-β-cyclodextrin (HPBCD) and polyethylene glycol (PEG). This formulation enhances plasma and brain exposure of Vo in mice and rat models and shows specific activity in the spared nerve injury (SNI) model of chronic neuropathic pain. TCF (but not HPBCD and PEG) decreased mechanical allodynia for 4 weeks without antagonizing weight, anxiety, or mobility. This was achieved at less than 1% of the total dose of Vo approved for 4 weeks of tumor treatment, decreased RNA levels of two major inflammatory markers (CD11b and GFAP), and reduced proliferation of microglia in the ipsilateral (but not contralateral) spinal cord. A single TCF injection was sufficient for 3-4 weeks of efficacy. Pharmacodynamics suggested pain relief was sustained for weeks after Vo elimination. Doubling Vo in a single TCF injection tripled the response amplitude and remained effective for > 2 months in male rats. Together, these data suggest that the TCF enables single-dose effectiveness with extended action, reduces long-term HDACi dosage, and presents excellent potential to develop as a non-opioid treatment option for chronic pain. PERSPECTIVE: An epigenetic drug formulation (TCF) tested in rat and mouse chronic neuropathic pain models shows adequate and persistent pain relief, engaging spinal cord inflammatory mechanisms.

2025-05-01·Clinical Lymphoma Myeloma & Leukemia

A Phase I Study of Romidepsin in Combination With Gemcitabine, Oxaliplatin, and Dexamethasone in Patients With Relapsed or Refractory Aggressive Lymphomas Enriched for T-Cell Lymphomas

Article

作者: Fehniger, Todd A ; Bartlett, Nancy L ; Moreno, Chaz ; Kahl, Brad S ; Carson, Kenneth R ; Fischer, Anne ; Foley, Nicole ; Mehta-Shah, Neha ; Liu, Jingxia ; Riedell, Peter A ; Cashen, Amanda F

INTRODUCTION:

Histone deacetylase inhibitors (HDACi) and combination chemotherapy are independently used to treat relapsed/refractory (R/R) lymphoma. In vitro studies suggest that the addition of HDACi to platinum-based chemotherapy is synergistic.

PATIENTS AND METHODS:

We conducted a phase I study of romidepsin, gemcitabine, oxaliplatin and dexamethasone (Romi-GemOxD) in R/R aggressive lymphomas with an expansion cohort in T-cell lymphomas. A total of 24 patients were enrolled with median age 70; 6 patients had diffuse large B-cell lymphoma (DLBCL) and 18 patients had peripheral T-cell lymphomas (PTCL-NOS: 10; angioimmunoblastic T-cell lymphoma [AITL]: 7; ALK-negative anaplastic large cell lymphoma: 1). Patients had received a median of 2 prior lines of therapy and 10 patients were refractory to last line of therapy.

RESULTS:

Using a standard 3 + 3 dose escalation design, the maximum tolerated dose of romidepsin was determined to be 10 mg/m² in combination with GemOxD. There were no unexpected toxicities. The most common grade ≥ 3 treatment-emergent adverse events were thrombocytopenia (79%) and lymphopenia (46%). The overall response rate for Romi-GemOxD was 52% (12/23) with complete response (CR) rate of 43% (10/23). All 6 patients with AITL evaluable for efficacy achieved CR. Durable responses were seen in patients with AITL, PTCL-NOS and DLBCL. Without additional therapy, 4 patients remained in remission for more than 2 years, with 3 patients progressing at 46.5, 30.8, and 32.6 months and 1 remission ongoing at 83 months. A total of 4 patients proceeded to consolidative stem cell transplant following induction.

CONCLUSION:

Romi-GemOxD represents a well-tolerated, time-limited, effective option for patients, particularly for those with AITL in which durable responses were seen. NCT02181218.

2025-05-01·INTERNATIONAL IMMUNOPHARMACOLOGY

Rituximab-Chidamide combination chemotherapy enhances autophagy to overcome drug resistance in diffuse large B-cell lymphoma

Article

作者: Wu, Zelai ; Ning, Daohua ; Gu, Shanshan ; Fu, Di ; Wang, Dongni

Diffuse large B-cell lymphoma (DLBCL) is a challenging malignancy, particularly when resistance to standard therapies such as Rituximab develops. This study investigates the combined therapeutic effects of Rituximab and Chidamide on DLBCL, focusing on drug resistance mechanisms and autophagy regulation. Using high-throughput proteomics and transcriptomic analyses, key proteins and signaling pathways were identified. BTG1 emerged as a signature gene, while autophagy-related genes such as BECN1, ATG5, HSPA8, PTEN, and MAPK8 were highlighted as pivotal players. In vitro experiments using Rituximab-sensitive and -resistant DLBCL cell lines (Raji and Raji-4RH) demonstrated that Chidamide significantly inhibited cell proliferation in a dose- and time-dependent manner, induced G0/G1 phase arrest, and enhanced autophagy. Mechanistically, Chidamide upregulated histone acetylation and autophagy-related proteins while reducing p62 levels, synergistically promoting autophagy with Rituximab. In vivo mouse models confirmed the combined treatment's efficacy in suppressing tumor growth. These findings suggest that the BTG1/BECN1/ATG5 signaling axis plays a critical role in enhancing autophagy and reversing Rituximab resistance. The combination of Chidamide and Rituximab presents a promising therapeutic strategy, offering new insights into overcoming drug resistance in DLBCL.

234

项与西达本胺相关的新闻（医药）

8 小时之前

·ioncology

18-ICML·抢先看丨汇聚中国风采！第18届国际恶性淋巴瘤会议17项口头报告及30项壁报全景呈现

由瑞士肿瘤研究所基金会（IOR）主办的第18届国际恶性淋巴瘤会议（18-ICML）将于2025年6月17日至21日在瑞士卢加诺会议中心（Palazzo dei Congressi）召开。作为全球血液肿瘤学领域最具影响力的两年一度的学术盛会，本届会议预计汇聚来自全球的千余名血液学家、临床肿瘤学家、放射肿瘤学家、儿科医生、病理学家及淋巴瘤研究领域的前沿学者，共同探讨疾病机制、转化医学进展及临床诊疗创新。在本次盛会中，中国学者以丰富的学术成果为会议增光添彩，共呈现17项口头报告及30项壁报展示（截至2025年5月12日）。《肿瘤瞭望-血液时讯》特此系统梳理研究成果，旨在为临床医师及科研工作者提供学术风向标，助力我国淋巴瘤诊疗水平的提升。口头报告（ORAL）*汇报时间均为当地时间1淋巴瘤放射治疗研讨会LYMPHOMA RADIOTHERAPY WORKSHOP中文题目：现今应该采用哪种全身治疗方案？英文题目：Which systemic regimen should be used today?发言人：中山大学附属肿瘤医院蔡清清教授时间：6.17 16:15地点：Cinema Corso中文题目：现代系统性治疗背景下早期阶段的放射剂量与照射体积英文题目：Radiation doses and volumes in early stages with modern systemic therapy发言人：Shunan Qi（北京）时间：6.17 16:30地点：Cinema Corso2聚焦专场-进行中的临床试验“FOCUS ON…” SESSIONS-ONGOING TRIALS中文题目：GUIDANCE-02：一项关于遗传亚型指导的免疫化疗在弥漫大B细胞淋巴瘤中的多中心随机III期研究英文题目：GUIDANCE-02: A multi-center randomized phase 3 study of genetic subtype-guided immunochemotherapy in diffuse large B-cell lymphoma摘要号：OT5发言人：上海交通大学医学院附属瑞金医院赵维莅教授时间：6.18 17:40地点：Cinema Corso3儿童淋巴瘤PEDIATRIC LYMPHOMAS中文题目：中国T细胞淋巴母细胞淋巴瘤儿科患者中融合基因的发生频率及其临床影响英文题目：Frequency of fusion genes and their clinical impacts in Chinese pediatric patients with T cell lymphoblastic lymphoma摘要号：36发言人：高博医学（血液病）北京研究中心北京高博博仁医院医疗张永红教授时间：6.19 15:55地点：Auditorium, West Campus USI中文题目：53例复发或难治性儿童ALK阳性间变性大细胞淋巴瘤的临床分析英文题目：Clinical analysis of 53 cases of relapsed or refractory childhood ALK + anaplastic large cell lymphoma摘要号：38发言人：高博医学（血液病）北京研究中心王凯教授时间：6.19 16:15地点：Auditorium, West Campus USI4套细胞淋巴瘤MANTLE CELL LYMPHOMA中文题目：奥布替尼、来那度胺联合利妥昔单抗作为套细胞淋巴瘤一线治疗的新型三联方案：POLARIS多中心II期研究的最终结果英文题目：Novel Triplet Combination of Orelabrutinib, Lenalidomide, and Rituximab as Frontline Therapy for Mantle Cell Lymphoma: Final Results of POLARIS Multicenter Phase II Study摘要号：48发言人：天津医科大学肿瘤医院宋拯教授时间：6.19 16:15地点：Room A.bradcast in Ginema Corso5早期临床试验EARLY CLINICAL TRIALS中文题目：DZD8586在经共价或非共价BTK抑制剂及BTK降解剂治疗后的慢性淋巴细胞白血病/小淋巴细胞淋巴瘤患者中的I/II期研究英文题目：Phase 1/2 Studies of DZD8586 in CLL/SLL Patients after Covalent or Non-covalent BTKInhibitors and BTK Degraders摘要号：146发言人：南京医科大学第一附属医院（江苏省人民医院）李建勇教授时间：6.19 17:35地点：Auditorium, West Campus USI7NK/T细胞淋巴瘤NK/T-CELL LYMPHOMA中文题目：SHR2554（一种口服性EZH2抑制剂）在复发或难治性外周T细胞淋巴瘤中的关键性研究英文题目：A Pivotal Study of SHR2554, An Oral Inhibitor Against Enhancer of Zeste Homolog 2 (EZH2), in Relapsed or Refractory (r/r) Peripheral T-cell Lymphoma (PTCL)摘要号：61发言人：北京大学肿瘤医院宋玉琴教授时间：6.20 09 :15地点：Room B,broadcast in Marquee Parco Ciani中文题目：帕博利珠单抗联合放疗治疗新诊断早期自然杀伤/T细胞淋巴瘤虚弱患者的Ⅱ期临床试验（IELSG50）英文题目：A Phase II Trial of Pembrolizumab Concurrent with Radiotherapy for Frail Patients with Newly Diagnosed Early-stage Natural Killer/T-cell Lymphoma (IELSG50)摘要号：62发言人：上海交通大学医学院附属瑞金医院赵维莅教授时间：6.20 09 :30地点：Room B,broadcast in Marquee Parco Ciani中文题目：卡瑞利珠单抗联合低剂量阿帕替尼及培门冬酶后行放疗治疗新诊断Ⅰ/Ⅱ期自然杀伤/T细胞淋巴瘤：一项多中心Ⅱ期研究英文题目：Camrelizumab plus low-dose apatinib and pegaspargase followed by radiotherapy for newly diagnosed stage I/II natural killer/T-cell lymphoma: a multicenter phase II study摘要号：63发言人：Chuanxu Liu（上海）时间：6.20 09 :45地点：Room B,broadcast in Marquee Parco Ciani8淋巴瘤研究：来自中国与欧洲的最新进展LYMPHOMA RESEARCH: NEWS FROM CHINA AND EUROPE中文题目：弥漫性大B细胞淋巴瘤治疗进展：中国视角亮点英文题目：Advances in DLBCL Management: Highlights from China摘要号：UCLI1发言人：哈尔滨血液病肿瘤研究所赵东陆教授时间：6.20 14:35地点：Polivalente room,East Campus USI中文题目：液体活检技术在淋巴瘤领域的最新进展英文题目：State-of-the-art of Liquid Biopsy in Lymphoma摘要号：UCLI3发言人：Meng Wu（北京）时间：6.20 14:55地点：Polivalente room,East Campus USI中文题目：中国新型药物在惰性淋巴瘤治疗中的国际应用概述英文题目：International Overview of Chinese Novel Drugs in Indolent Lymphoma摘要号：UCLI5发言人：吉林大学白求恩第一医院白鸥教授时间：6.20 16:15地点：Polivalente room,East Campus USI9新型药物NEW DRUGS中文题目：一项评估选择性 EZH2 抑制剂-XNW5004 在复发/难治性非霍奇金淋巴瘤受试者中安全性和有效性的 1/2 期研究英文题目：A Phase 1/2 study to evaluate the safety and efficacy of XNW5004, a selective EZH2 inhibitor, in subjects with relapsed/ refractory non-Hodgkin lymphoma摘要号：95发言人：中国医学科学院血液病医院（中国医学科学院血液学研究所）邱录贵教授时间：6:21 10:30地点：Room A10T细胞淋巴瘤的生物学与治疗BIOLOGY AND THERAPY OF T-CELL LYMPHOMAS中文题目：他泽司他联合Amdizalisib 治疗具有不同基因组特征的复发或难治性外周T细胞淋巴瘤患者：一项Ⅱ期研究结果英文题目：Tazemetostat plus Amdizalisib in Relapsed/Refractory Peripheral T-cell Lymphoma Patients with Diverse Genomic Signatures: Results from a Phase 2 Study摘要号：163发言人：上海交通大学医学院附属瑞金医院程澍教授时间：6:21 09:55地点：Room B中文题目：林普利塞联合CHOP方案治疗新诊断外周T细胞淋巴瘤：一项单臂、开放标签、多中心Ⅰb/Ⅱ期研究（LINCH试验）英文题目：Linperlisib Plus CHOP for Newly Diagnosed Peripheral T-Cell Lymphoma: A Single-Arm,Open-Lable, Multi-Center Phase Ib/II Study (LINCH Trial)摘要号：165发言人：中山大学附属肿瘤医院蔡清清教授时间：6.21 10:15地点：Room B中文题目：戈利昔替尼（一种选择性JAK1抑制剂）作为一线全身治疗后外周T细胞淋巴瘤患者维持治疗的疗效更新：Ⅱ期研究（JACKPOT26）进展英文题目：Maintenance Therapy of Golidocitinib, a JAK1 Selective Inhibitor, in Patients with PTCLs after First-line Systemic Therapy: Updates of the Phase 2 Study (JACKPOT26)摘要号：167发言人：浙江大学医学院附属第一医院金洁教授时间：6.21 10:35地点：Room B壁报展示（POSTER）1淋巴瘤生物学Lymphoma biology中文题目：稳定化MYCT58A突变绕过T细胞辅助作用驱动生发中心B细胞淋巴瘤发生英文题目：Stabilized MYCT58A Bypasses T-Cell Help to Fuel Germinal Center B-Cell Lymphomagenesis摘要号：171作者：Baizhi Chen2淋巴瘤遗传学Lymphoma genetics中文题目：EGR2基因突变预示接受布鲁顿酪氨酸激酶抑制剂治疗的慢性淋巴细胞白血病患者预后不良英文题目：EGR2 mutations Confer Poor Prognosis in Chronic Lymphocytic Leukemia Treated with Bruton Tyrosine Kinase Inhibitors摘要号：176作者：Huayuan Zhu中文题目：结外受累滤泡性淋巴瘤的临床特征与分子异质性分析英文题目：Clinical characteristics and molecular heterogeneity in Follicular Lymphoma with extranodal involvement摘要号：178作者：赵维莅3淋巴瘤分类Lymphoma classification中文题目：全基因组测序揭示三种具有不同起源细胞特征和患者预后的滤泡性淋巴瘤亚型英文题目：Whole-genome sequencing reveals three follicular lymphoma subtypes with distinct cell-of-origin and patient outcomes摘要号：193作者：Weicheng Ren中文题目：多组学解析EB病毒驱动的结外NK/T细胞淋巴瘤进展中的异质性、代谢重塑及肿瘤细胞图谱英文题目：Multi-omics dissection of EBV-driven heterogeneity, metabolic remodeling, and tumor cellular landscape in ENKTL progression摘要号：195作者：梁金花4慢性淋巴细胞白血病Chronic lymphocytic leukemia中文题目：癌前生发中心B细胞的免疫监视机制研究英文题目：Immunosurveillance of Precancerous Germinal Center B Cells摘要号：202作者：LINGLING ZHANG中文题目：空间组学与单细胞多组学揭示原发性中枢神经系统淋巴瘤与弥漫大B细胞淋巴瘤的巨噬细胞异质性英文题目：Spatial and Single-Cell Multi-omics Reveal Macrophage Heterogeneity between Primary CNS Lymphoma (PCNSL) and Diffuse Large B-Cell Lymphoma (DLBCL)摘要号：206作者：Liang Hong5边缘区与淋巴浆细胞性淋巴瘤Marginal zone and lymphoplasmacytic lymphoma中文题目：奥布替尼联合奥妥珠单抗（O2方案）一线治疗边缘区淋巴瘤的疗效、安全性及合理性：前瞻性队列研究英文题目：The efficacy, safety and rationality of Orelabrutinib plus Obinutuzumab (O2) in systemic treatment-naïve marginal zone lymphoma: a prospective cohort study摘要号：255作者：Jiadai Xu6套细胞淋巴瘤Mantle Cell Lymphoma中文题目：非结节性套细胞淋巴瘤未必等同于惰性MCL：LEO队列研究的临床观察英文题目：Leukemic non-nodal mantle cell lymphoma (nnMCL) is not necessarily equivalent to indolent MCL: A report from the LEO Cohort Study.摘要号：271作者：Tony Zibo Zhuang7侵袭性B细胞淋巴瘤——一线临床试验Aggressive B-cell lymphomas-first line clinical trials中文题目：新型ZCR方案（泽布替尼、西达本胺、利妥昔单抗）±CHOP方案在双表达弥漫大B细胞淋巴瘤一线治疗中展现显著疗效英文题目：Novel ZCR (Zanubrutinib, Chidamide, Rituximab) ± CHOP Regimen Demonstrates Promising Efficacy in Frontline Treatment of Double-Expressor Diffuse Large B-Cell Lymphoma摘要号：284作者：Zhiming Li中文题目：维泊妥珠单抗、泽布替尼联合利妥昔单抗（Pola-ZR方案）治疗初治老年及虚弱DLBCL患者的疗效与安全性：前瞻性Ⅱ期临床试验英文题目：Efficacy and Safety of Polatuzumab Vedotin, Zanubrutinib and Rituximab (Pola-ZR) in Untreated Elderly and Frail DLBCL Patients: A Prospective Phase 2 Clinical Trial摘要号：285作者：Yuhong Ren8侵袭性B细胞淋巴瘤治疗结果Aggressive B-cell lymphomas outcomes中文题目：POLARIX研究5年亚组分析：亚洲未经治疗的DLBCL患者中Pola-R-CHP方案的疗效获益验证英文题目：Five-Year Analysis of an Asia Subpopulation with Previously Untreated DLBCL Confirms Pola-R-CHP Benefit on Outcomes: The POLARIX Study摘要号：288作者：宋玉琴中文题目：中国大规模真实世界研究：不同基因亚型弥漫大B细胞淋巴瘤的临床实践模式与预后差异英文题目：Clinical practice pattern and outcomes in DLBCL with distinct genetic subtypes: a large-scale real-world study from China摘要号：294作者：许彭鹏9复发/难治性侵袭性B细胞淋巴瘤：临床试验Relapsed/refractory aggressive B-cell lymphomas: clinical trials中文题目：分子亚型指导的R-MINE+X方案治疗复发/难治性弥漫大B细胞淋巴瘤：单臂开放标签多中心Ⅱ期研究英文题目：Molecular Subtype-Guided R-MINE+X Regimen in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Single-arm, Open-label, Multicenter Phase II Study摘要号：317作者：梁金花10中枢神经系统淋巴瘤CNS Lymphomas中文题目：MEDZ-R方案治疗新诊断原发性中枢神经系统淋巴瘤的多中心前瞻性Ⅱ期临床试验英文题目：A multi-center prospective phase II clinical trial of the MEDZ-R regimen for the treatment of newly diagnosed primary central nervous system lymphoma摘要号：332作者：li Zou中文题目：利妥昔单抗联合大剂量甲氨蝶呤及奥布替尼作为新诊断原发性中枢神经系统淋巴瘤的诱导治疗方案英文题目：Rituximab, high-dose methotrexate plus orelabrutinib as induction therapy in newly diagnosed primary central nervous system lymphoma摘要号：333作者：Wenrong Huang中文题目：奥布替尼联合抗PD-1抗体与福莫司汀治疗新诊断原发性中枢神经系统淋巴瘤的Ⅰ/Ⅱ期研究英文题目：A Phase I/II Study of Orelabrutinib Combined with Anti-PD-1 Antibody and Fotemustine for Patients with Newly Diagnosed Primary Central Nervous System Lymphoma (PCNSL)摘要号：334作者：Wanyue Zhao11原发性纵隔淋巴瘤Primary mediastinal lymphoma中文题目：替雷利珠单抗联合R-CHOP方案治疗初治原发性纵隔大B细胞淋巴瘤：前瞻性Ⅱ期临床试验英文题目：Anti-PD-1 antibody (Tislelizumab) combined with R-CHOP for the treatment of previously untreated primary mediastinal B-cell lymphoma: A prospective phase II study摘要号：347作者：Wen Shu juan12霍奇金淋巴瘤Hodgkin Lymphoma中文题目：老年霍奇金淋巴瘤治疗格局演变与预后分析：中国15年多中心回顾性研究揭示新型疗法影响英文题目：Evolving Treatment Landscape and Outcomes in Elderly Hodgkin Lymphoma: A 15-Year Multicenter Retrospective Analysis from China Highlighting the Impact of Novel Therapies摘要号：366作者：赵培起13儿科淋巴瘤Pediatric lymphomas中文题目：中国南方真实世界研究：PD-1抗体单药及联合方案治疗儿童淋巴瘤的疗效与安全性英文题目：real world study of efficacy and safety of PD-1 antibody monotherapy and combination therapy in pediatric lymphoma patients in South China摘要号：375作者：Jia Zhu中文题目：儿童、青少年及青年霍奇金淋巴瘤长期生存者的晚期并发症与生活质评估英文题目：Late Complications and Quality of Life in Long-Term Survivors of Childhood, Adolescent, and Young Adult Hodgkin Lymphoma摘要号：377作者：Linnan Wu14NK/T细胞淋巴瘤NK/T-cell Lymphomas中文题目：EGF-JAK/STAT通路突变对血管免疫母细胞性T细胞淋巴瘤的预后及功能影响研究英文题目：Prognostic and Functional Impact of EGF-JAK/STAT Pathway Mutations in Angioimmunoblastic T-cell Lymphoma (AITL)摘要号：384作者：DACHUAN HUANG中文题目：全血EB病毒DNA载量在血管免疫母细胞性T细胞淋巴瘤中的预后价值分析英文题目：The prognostic role of whole blood Epstein‑Barr virus DNA load in angioimmunoblastic T-cell lymphoma摘要号：385作者：Yi Zhong中文题目：阿扎胞苷联合西达本胺及CHOP方案对比CHOP方案治疗初治外周T细胞淋巴瘤的Ⅱ期研究英文题目：A phase II study of azacitidine and chidamide plus CHOP versus CHOP in previously untreated patients with peripheral T-cell lymphoma摘要号：391作者：Chong Wei中文题目：西达本胺联合阿扎胞苷、米托蒽醌脂质体及泼尼松（CAMP方案）治疗TFH来源的初治外周T细胞淋巴瘤英文题目：Chidamide in combination with azacitidine, mitoxantrone liposomes, and prednisone (CAMP regimen) for treatment-naïve TFH-derived peripheral T-cell lymphoma摘要号：392作者：Huimin Liu中文题目：PD-1抑制剂信迪利单抗联合培门冬酶与安罗替尼治疗Ⅳ期NK/T细胞淋巴瘤的疗效与安全性：多中心前瞻性研究英文题目：A Multi-center, Prospective Study of the Efficacy and Safety of PD-1 Antibody Sintilimab in Combination With Pegaspargase and Anlotinib in Stage IV NKTCL Patients摘要号：400作者：Rong Tao15多发性骨髓瘤Multiple Myeloma中文题目：塞利尼索联合硼替佐米、来那度胺及地塞米松治疗高危初治多发性骨髓瘤的单臂多中心观察性研究英文题目：A single-arm, multi-center, observational study of Selinexor combined bortezomib, lenalidomide, and dexamethasone in high-risk newly diagnosed multiple myeloma(NDMM) 摘要号：403作者：Yuping Zhong16液体活检Liquid Biopsy中文题目：动态ctDNA监测揭示的分子特征：不同基因亚型弥漫大B细胞淋巴瘤的预后价值、临床病程及克隆演化规律英文题目：Molecular features encoded in the dynamic ctDNA monitoring reveal prognostic value, different clinical courses and clone evolution for different genetic subtypes of DLBCL摘要号：422作者：梁金花17新型组合Novel compounds中文题目：泽布替尼联合来那度胺治疗复发/难治性弥漫大B细胞淋巴瘤的Ⅰ期临床研究分析英文题目：Analysis of a Phase 1 Study of Zanubrutinib (Zanu) + Lenalidomide (Len) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)摘要号：439作者：张会来18新型细胞疗法New cellular therapies中文题目：携带OX40信号的CAR-T疗法驱动CD4+T细胞克隆扩增并克服B细胞淋巴瘤免疫抑制微环境：Ⅰ期临床试验英文题目：CAR-T Therapy with OX40 Signaling Drives Clonal Expansion of CD4+ T Cells and Overcomes Immunosuppressive Microenvironment in B-Cell Lymphoma: A Phase I Trial摘要号：466作者：Ling-Shuang Sheng*因官网尚未公布详细壁报信息，可能出现错漏，敬请谅解《肿瘤瞭望-血液时讯》将全程追踪并深度解析18-ICML的学术动态与会议进展，诚邀广大血液肿瘤领域临床工作者及研究人员持续关注本刊后续报道！（来源：《肿瘤瞭望–血液时讯》编辑部）声明凡署名原创的文章版权属《肿瘤瞭望》所有，欢迎分享、转载。本文仅供医疗卫生专业人士了解最新医药资讯参考使用，不代表本平台观点。该等信息不能以任何方式取代专业的医疗指导，也不应被视为诊疗建议，如果该信息被用于资讯以外的目的，本站及作者不承担相关责任。

放射疗法临床2期

2025-05-07

·cerenoscientific.com

Cereno Scientific's Nomination Committee proposes new Board with M&A profile ahead of the Annual General Meeting on May 10, 2025

The Nomination Committee of Cereno Scientific AB (publ) (the “Company”) has today decided to propose a new Board of Directors at the Annual General Meeting on June 10, 2025, with particular expertise in M&A/partnering and business development (BD). The Nomination Committee’s proposal means that Jeppe Øvlesen is proposed as the new Chairman of the Board, that Moi Brajanovic is proposed to be newly elected as a Board member and that Joakim Söderström is not proposed to be a member of the Board. The other Board members Anders Svensson, Gunnar Olsson and Sten R. Sörensen are proposed to be re-elected. The Nomination Committee, in accordance with the principles adopted by the previous Annual General Meeting, consists of Andreas Ejlegård (Chairman), Joakim Söderström and Björn Dahlöf. The Nomination Committee proposes the following Board: re-election of Board members Anders Svensson, Jeppe Øvlesen, Gunnar Olsson and Sten R. Sörensen and new election of board member Moi Brajanovic. Jeppe Øvlesen is proposed to be elected as Chairman of the Board (new election). Statement from the Nomination Committee Chairman Andreas Ejlegård: "The Nomination Committee has noted that the company is now entering a new phase with an increased focus on M&A and BD. Joakim Söderström has led the work of the Board in an exemplary manner during the last two terms of office. Although he has been available to the Nomination Committee for re-election, the Nomination Committee believes that a change in leadership on the Board is important to optimize the company's conditions in the upcoming phase. Against this background, the Nomination Committee proposes a new composition of the Board to strengthen the opportunities to achieve the company's strategic goals. Jeppe Øvlesen is an internationally recognized authority in dealmaking and has the experience and competence required to successfully lead this work forward. With Moi Brajanovic as a new member, the Board is provided with important expertise in business development and transactions - two key areas to drive the company to realize its strategic goals.” Moi Brajanovic (born 1987) holds a degree of master in economics with a focus on Business Administration from the School of Business, Economics and Law at the University of Gothenburg. Moi has extensive international experience from the finance sector, with a strong background in business development, due diligence and transactions (M&A). During his career, Moi has led complex risk and capital management assignments for international financial institutions. Moi is currently Managing Director at Advisense, a leading European company within governance, risk and compliance. The Nomination Committee’s other proposals will be presented in the notice of the Annual General Meeting that the Company plans to publish on Friday, May 9, 2025. For further information, please contact: Tove Bergenholt, Head of IR & Communications Email: tove.bergenholt@cerenoscientific.com Phone: +46 73- 236 62 46 This information is information that Cereno Scientific AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 14:00 (CET) on May 7, 2025. About Cereno Scientific AB Cereno Scientific is pioneering treatments to enhance and extend life. Our innovative pipeline offers disease-modifying drug candidates to empower people suffering from rare cardiovascular and pulmonary diseases to live life to the full. Lead candidate CS1 is an HDACi that works through epigenetic modulation, being developed as an effective and disease modifying treatment with a favorable safety and tolerability profile for rare disease Pulmonary Arterial Hypertension (PAH). A Phase IIa trial evaluating CS1’s safety, tolerability, and exploratory efficacy in patients with PAH demonstrated that CS1 has a favorable safety profile, is well-tolerated and showed a positive impact on exploratory clinical efficacy parameters. An Expanded Access Program enables patients that have completed the Phase IIa trial to gain access to CS1. CS014, in Phase I development, is a new chemical entity with disease-modifying potential. CS014 is a HDAC inhibitor with a multimodal mechanism of action as an epigenetic modulator having the potential to address the underlying pathophysiology of rare cardiovascular and pulmonary diseases with high unmet needs such as idiopathic pulmonary fibrosis (IPF). Cereno Scientific is also pursuing a preclinical program with CS585, an oral, highly potent and selective prostacyclin (IP) receptor agonist that has demonstrated the potential to significantly improve disease mechanisms relevant to cardiovascular diseases. While CS585 has not yet been assigned a specific indication for clinical development, preclinical data indicates that it could potentially be used in indications like Thrombosis prevention without increased risk of bleeding and Pulmonary Hypertension. The Company is headquartered in GoCo Health Innovation City, in Gothenburg, Sweden, and has a US subsidiary; Cereno Scientific Inc. based in Kendall Square, Boston, Massachusetts, US. Cereno Scientific is listed on the Nasdaq First North (CRNO B). The Certified Adviser is Carnegie Investment Bank AB, certifiedadviser@carnegie.se. More information can be found on www.cerenoscientific.com. Read PDF Share

临床1期临床2期高管变更临床结果

2025-05-07

·cerenoscientific.com

Correction: Cereno Scientific's Nomination Committee proposes new Board with M&A profile ahead of the Annual General Meeting on June 10, 2025

Correction: Thie previous press release stated the wrong date for the Annual General Meeting 2025. The Nomination Committee of Cereno Scientific AB (publ) (the “Company”) has today decided to propose a new Board of Directors at the Annual General Meeting on June 10, 2025, with particular expertise in M&A/partnering and business development (BD). The Nomination Committee’s proposal means that Jeppe Øvlesen is proposed as the new Chairman of the Board, that Moi Brajanovic is proposed to be newly elected as a Board member and that Joakim Söderström is not proposed to be a member of the Board. The other Board members Anders Svensson, Gunnar Olsson and Sten R. Sörensen are proposed to be re-elected. The Nomination Committee, in accordance with the principles adopted by the previous Annual General Meeting, consists of Andreas Ejlegård (Chairman), Joakim Söderström and Björn Dahlöf. The Nomination Committee proposes the following Board: re-election of Board members Anders Svensson, Jeppe Øvlesen, Gunnar Olsson and Sten R. Sörensen and new election of board member Moi Brajanovic. Jeppe Øvlesen is proposed to be elected as Chairman of the Board (new election). Statement from the Nomination Committee Chairman Andreas Ejlegård: "The Nomination Committee has noted that the company is now entering a new phase with an increased focus on M&A and BD. Joakim Söderström has led the work of the Board in an exemplary manner during the last two terms of office. Although he has been available to the Nomination Committee for re-election, the Nomination Committee believes that a change in leadership on the Board is important to optimize the company's conditions in the upcoming phase. Against this background, the Nomination Committee proposes a new composition of the Board to strengthen the opportunities to achieve the company's strategic goals. Jeppe Øvlesen is an internationally recognized authority in dealmaking and has the experience and competence required to successfully lead this work forward. With Moi Brajanovic as a new member, the Board is provided with important expertise in business development and transactions - two key areas to drive the company to realize its strategic goals.” Moi Brajanovic (born 1987) holds a degree of master in economics with a focus on Business Administration from the School of Business, Economics and Law at the University of Gothenburg. Moi has extensive international experience from the finance sector, with a strong background in business development, due diligence and transactions (M&A). During his career, Moi has led complex risk and capital management assignments for international financial institutions. Moi is currently Managing Director at Advisense, a leading European company within governance, risk and compliance. The Nomination Committee’s other proposals will be presented in the notice of the Annual General Meeting that the Company plans to publish on Friday, May 9, 2025. For further information, please contact: Tove Bergenholt, Head of IR & Communications Email: tove.bergenholt@cerenoscientific.com Phone: +46 73- 236 62 46 This information is information that Cereno Scientific AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 14:30 (CET) on May 7, 2025. About Cereno Scientific AB Cereno Scientific is pioneering treatments to enhance and extend life. Our innovative pipeline offers disease-modifying drug candidates to empower people suffering from rare cardiovascular and pulmonary diseases to live life to the full. Lead candidate CS1 is an HDACi that works through epigenetic modulation, being developed as an effective and disease modifying treatment with a favorable safety and tolerability profile for rare disease Pulmonary Arterial Hypertension (PAH). A Phase IIa trial evaluating CS1’s safety, tolerability, and exploratory efficacy in patients with PAH demonstrated that CS1 has a favorable safety profile, is well-tolerated and showed a positive impact on exploratory clinical efficacy parameters. An Expanded Access Program enables patients that have completed the Phase IIa trial to gain access to CS1. CS014, in Phase I development, is a new chemical entity with disease-modifying potential. CS014 is a HDAC inhibitor with a multimodal mechanism of action as an epigenetic modulator having the potential to address the underlying pathophysiology of rare cardiovascular and pulmonary diseases with high unmet needs such as idiopathic pulmonary fibrosis (IPF). Cereno Scientific is also pursuing a preclinical program with CS585, an oral, highly potent and selective prostacyclin (IP) receptor agonist that has demonstrated the potential to significantly improve disease mechanisms relevant to cardiovascular diseases. While CS585 has not yet been assigned a specific indication for clinical development, preclinical data indicates that it could potentially be used in indications like Thrombosis prevention without increased risk of bleeding and Pulmonary Hypertension. The Company is headquartered in GoCo Health Innovation City, in Gothenburg, Sweden, and has a US subsidiary; Cereno Scientific Inc. based in Kendall Square, Boston, Massachusetts, US. Cereno Scientific is listed on the Nasdaq First North (CRNO B). The Certified Adviser is Carnegie Investment Bank AB, certifiedadviser@carnegie.se. More information can be found on www.cerenoscientific.com. Read PDF Share

临床2期临床1期高管变更临床结果

100 项与西达本胺相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	西达本胺	L01XX	DB06334

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
弥漫性大B细胞淋巴瘤	中国	深圳微芯生物科技股份有限公司	2024-04-24
成人T细胞白血病/淋巴瘤	日本	Meiji Seika Pharma Co., Ltd.	2021-06-23
乳腺癌	中国	深圳微芯生物科技股份有限公司	2019-11-20
外周T细胞淋巴瘤	中国	深圳微芯生物科技股份有限公司	2014-12-23

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
微卫星稳定型结直肠癌	临床3期	中国	深圳微芯生物科技股份有限公司	2024-11-27
不能切除的大肠癌	临床3期	中国	深圳微芯生物科技股份有限公司	2024-11-27
转移性微卫星稳定结直肠癌	临床3期	中国	中山大学	2023-03-01
MSI 癌症	临床3期	中国	中山大学	2023-03-01
脑转移瘤	临床3期	美国	Bristol Myers Squibb Co.	2021-08-12
脑转移瘤	临床3期	美国	HUYA Bioscience International LLC	2021-08-12
脑转移瘤	临床3期	日本	HUYA Bioscience International LLC	2021-08-12
脑转移瘤	临床3期	日本	Bristol Myers Squibb Co.	2021-08-12
脑转移瘤	临床3期	澳大利亚	HUYA Bioscience International LLC	2021-08-12
脑转移瘤	临床3期	澳大利亚	Bristol Myers Squibb Co.	2021-08-12

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05659992 (Pubmed \| Front Immunol)	临床2期	急性髓性白血病 DNMTs \| HDACs	40	Chidamide + CAG + Venetoclax-Azacitidine	壓遞衊築廠顧壓衊願蓋(齋衊夢築簾壓夢構遞製) = 膚製顧鏇網齋鬱壓遞鹽廠築願遞壓築鏇廠構遞 (糧遞積鏇選膚範願選淵, 55.9 ~ 84.8) 更多	积极	2025-02-26
ChiCTR2200058431 (P-henomS/SCOG-P002, ASCO_GI2025) 人工标引	临床2期	胰腺癌二线	16	Chidamide + Envafolimab + S-1	選鏇壓構窪獵糧膚繭遞(築壓廠築願淵齋鏇獵鏇) = 構簾衊窪窪獵糧衊廠遞齋觸獵衊顧獵遞願築淵 (觸觸廠夢觸淵獵壓繭糧 ) 更多	积极	2025-01-23
NCT04661943 (4490Chidamide, ASH2024)	临床2期	乙型肝炎 \| 弥漫性大B细胞淋巴瘤维持	95	Chidamide maintenance therapy	餘範餘觸餘鏇繭築鬱鹽(範鏇繭顧襯衊淵繭鹹範) = neutropenia, anemia, thrombocytopenia 遞糧鹽網鹽鹽觸窪蓋衊 (鹽襯夢鏇觸觸醖窪襯觸 )	积极	2024-12-09
NCT04661943 (4490Chidamide, ASH2024)	临床2期	乙型肝炎 \| 弥漫性大B细胞淋巴瘤维持	95	Chidamide (Observation group)		积极	2024-12-09
NCT05566054 (ASH2024)	临床2期	急性髓性白血病	-	VAC regimen	簾壓憲獵積積膚醖鬱膚(醖憲鏇範廠繭蓋顧壓簾) = 網蓋憲鑰顧選簾鹽製襯鹹膚範範築鹽壓選願顧 (構獵夢膚窪蓋獵餘鬱艱 ) 更多	-	2024-12-07
NCT05566054 (ASH2024)	临床2期	急性髓性白血病	-	VA regimen	簾壓憲獵積積膚醖鬱膚(醖憲鏇範廠繭蓋顧壓簾) = 膚餘選選齋憲遞廠鑰醖鹹膚範範築鹽壓選願顧 (構獵夢膚窪蓋獵餘鬱艱 ) 更多	-	2024-12-07
ASH2024	N/A	复发性急性髓细胞白血病	-	Chidamide	蓋艱鑰蓋廠壓鹽齋構遞(顧夢襯齋艱積構範蓋膚) = one patient experienced grade 3/4 diarrhea 糧蓋淵顧壓簾蓋鏇願衊 (膚齋蓋獵築襯齋觸鏇築 ) 更多	-	2024-12-07
NCT02718066 (HBI-8000-302, SITC2024) 人工标引	临床1/2期	黑色素瘤	39	HBI-8000 + Nivolumab	簾積積膚網構夢齋鹽築(構積鹽醖憲襯構餘醖鬱) = 鏇遞壓憲廠廠衊夢艱齋醖築顧鏇襯憲願艱餘鹽 (蓋選齋觸鹽鹽鹽淵壓膚 ) 更多	积极	2024-11-05
NCT02955589 (Phase 2B Study, CTgov)	临床2期	成人T细胞白血病/淋巴瘤	23	HBI-8000	夢觸廠夢蓋膚鹹簾簾蓋 = 憲觸齋壓壓淵夢築觸構鬱憲窪製簾鹹廠簾夢廠 (淵壓選鹹鹹遞構網醖醖, 獵構選構獵餘顧壓糧觸 ~ 顧鬱憲繭積顧憲繭繭鏇) 更多	-	2024-09-19
ChiCTR2400080783 (B-Enefits/SCOG-B001, ESMO2024) 人工标引	临床2期	胆道癌一线	32	Envafolimabchidamide	淵窪齋膚衊壓獵遞淵壓(餘鑰積鏇構網構積顧觸) = 廠網鏇觸鑰憲鬱積鹽憲膚廠簾範構襯衊壓繭鏇 (蓋顧鹹艱繭簾鑰鏇鹽襯 ) 更多	积极	2024-09-16
NCT05411380 (ESMO2024) 人工标引	临床2期	HR阳性/HER2阴性乳腺癌 HER2 Negative \| Hormone Receptor Positive	43	Tucidinostatcapecitabine	願醖鹹選衊選壓膚範淵(壓鹹獵壓鹹範簾網願糧) = 顧簾簾鏇鬱願築餘觸夢襯鹽壓鹽窪範壓鏇鹽餘 (鹹簾積夢衊觸鏇憲獵願 ) 更多	积极	2024-09-16
NCT05527275 (ESMO2024) 人工标引	临床1/2期	外周T细胞淋巴瘤	21	PLM60achidamidedrochloride liposome (PLM60) plus chidamide (CHI)	壓蓋鹹蓋積齋範簾鬱膚(觸鏇鑰觸鑰築觸獵鹹遞) = 顧鏇鏇鬱顧製獵襯顧襯選繭衊獵鬱淵憲鹽鹹糧 (齋鹽夢鏇衊襯齋遞餘鬱, 29.9 ~ 80.2) 更多	积极	2024-09-15